Brokerages Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Price Target at $4.33

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the four analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.33.

Several research analysts recently commented on the company. Maxim Group reduced their price target on Oncolytics Biotech from $5.00 to $3.00 and set a "buy" rating for the company in a research report on Monday, March 10th. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Oncolytics Biotech in a research report on Wednesday, May 21st. Jones Trading reissued a "hold" rating on shares of Oncolytics Biotech in a research report on Friday, May 16th. Finally, Royal Bank Of Canada reduced their price target on Oncolytics Biotech from $6.00 to $5.00 and set an "outperform" rating for the company in a research report on Monday, March 10th.

Oncolytics Biotech Trading Up 23.8%

Shares of ONCY stock traded up $0.24 on Friday, hitting $1.25. 3,746,981 shares of the stock were exchanged, compared to its average volume of 700,230. The firm has a market capitalization of $117.85 million, a P/E ratio of -4.31 and a beta of 1.07. The business has a 50-day moving average of $0.57 and a 200 day moving average of $0.66. Oncolytics Biotech has a fifty-two week low of $0.33 and a fifty-two week high of $1.53.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.03. As a group, research analysts forecast that Oncolytics Biotech will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Oncolytics Biotech

A number of large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company's stock worth $61,000 after purchasing an additional 24,997 shares during the period. National Bank of Canada FI increased its stake in shares of Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company's stock worth $60,000 after purchasing an additional 42,955 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Oncolytics Biotech during the fourth quarter worth approximately $90,000. Institutional investors own 6.82% of the company's stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.